[1]李家德,钟永翔,陈永志,等.腰痛方颗粒联合抗骨质疏松药物治疗肝肾亏虚型老年性骨质疏松的效果[J].医学信息,2020,33(22):163-166.[doi:10.3969/j.issn.1006-1959.2020.22.048]
　LI Jia-de,ZHONG Yong-xiang,CHEN Yong-zhi,et al.Effect of Yaotongfang Granule Combined with Anti-osteoporosis Drugs on Senile Osteoporosis with Deficiency of Liver and Kidney[J].Medical Information,2020,33(22):163-166.[doi:10.3969/j.issn.1006-1959.2020.22.048]
点击复制

腰痛方颗粒联合抗骨质疏松药物治疗肝肾亏虚型老年性骨质疏松的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年22期
页码:
163-166
栏目:
中医中药
出版日期:
2020-11-15

文章信息/Info

Title:
Effect of Yaotongfang Granule Combined with Anti-osteoporosis Drugs on Senile Osteoporosis with Deficiency of Liver and Kidney
文章编号:
1006-1959（2020）22-0163-04
作者:
李家德; 钟永翔; 陈永志; 等
（台州市中西医结合医院骨科，浙江 台州 317523）
Author(s):
LI Jia-de; ZHONG Yong-xiang; CHEN Yong-zhi; et al
(Department of Orthopedics,Taizhou Integrated Traditional Chinese and Western Medicine Hospital,Taizhou 317523,Zhejiang,China)
关键词:
老年性骨质疏松; 腰痛方颗粒; 骨代谢; 骨密度
Keywords:
Senile osteoporosis; Yaotongfang granule; Bone metabolism; Bone density
分类号:
R274.1
DOI:
10.3969/j.issn.1006-1959.2020.22.048
文献标志码:
A
摘要:
目的 探讨腰痛方颗粒联合抗骨质疏松药物治疗肝肾亏虚型老年性骨质疏松的临床效果及对骨代谢指标的影响。方法 选择2016年1月~2017年12月我院收治的120例肝肾亏虚型老年骨质疏松患者作为研究对象，随机分为联合组与对照组，每组60例。对照组采用碳酸钙D3+阿仑膦酸钠片+骨化三醇治疗，联合组在此基础上加用腰痛方颗粒，比较两组临床疗效、治疗前、治疗后6、12个月VAS评分、骨密度（BMD）、血清抗酒石酸酸性磷酸酶（TRAP）、骨特异性碱性磷酸酶（BALP）及骨保护素（BGP）水平。结果 联合组治疗总有效率为96.66%，高于对照组的90.00%，差异有统计学意义（P＜0.05）；治疗6、12个月后，两组TRAP均较治疗前下降，且联合组低于对照组，差异有统计学意义（P＜0.05）；两组BALP、BGP较治疗前增加，且联合组高于对照组，差异有统计学意义（P＜0.05）；治疗后6、12个月两组 VAS评分均较治疗前降低，差异有统计学意义（P＜0.05）；治疗6、12个月后，两组平均BMD较治疗前增大，且治疗12个月后联合组BMD高于对照组，差异有统计学意义（P＜0.05）。结论 在抗骨质疏松药物治疗基础上联合复腰痛方颗粒能够改善肝肾亏虚型老年性骨质疏松患者的临床症状，有效降低骨代谢水平，增加腰椎骨密度，治疗效果较好，值得临床应用。
Abstract:
Objective To investigate the clinical effect of Yaotongfang granule combined with anti-osteoporosis drugs in treating senile osteoporosis of liver and kidney deficiency and its influence on bone metabolism indexes.Methods A total of 120 elderly osteoporosis patients with liver and kidney deficiency type who were admitted to our hospital from January 2016 to December 2017 were selected as the research objects, and they were randomly divided into a combination group and a control group, with 60 cases in each group. The control group was treated with calcium carbonate D3+alendronate sodium tablets+calcitriol, and the combination group was treated with Yaotongfang granule on this basis. The clinical efficacy, VAS scores before treatment, 6 and 12 months after treatment were compared between the two groups bone mineral density (BMD), serum anti-tartrate acid phosphatase (TRAP), bone-specific alkaline phosphatase (BALP) and osteoprotegerin (BGP) levels.Results The total effective rate of treatment in the combination group was 96.66%, which was higher than 90.00% in the control group, the difference was statistically significant (P<0.05); after 6 and 12 months of treatment, the TRAP of the two groups was lower than before treatment, and the combination group was lower In the control group, the difference was statistically significant (P<0.05); the two groups of BALP and BGP increased compared to before treatment, and the combination group was higher than the control group, the difference was statistically significant (P<0.05); after treatment 6, 12 the VAS scores of the two groups were lower than before treatment, the difference was statistically significant (P<0.05); after 6 and 12 months of treatment, the average BMD of the two groups was higher than that before treatment, and the BMD of the combined group was higher after 12 months of treatment the control group, the difference was statistically significant (P<0.05).Conclusion On the basis of anti-osteoporosis drug treatment, the combination of Fuyaotongfang Granule can improve the clinical symptoms of elderly osteoporosis patients with liver and kidney deficiency, effectively reduce the level of bone metabolism, and increase the bone density of the lumbar spine. The therapeutic effect is good and it is worth clinical application.

参考文献/References:

[1]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):413-436.[2]国家食品药品监督管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:341-342.[3]张江,关雪峰.中医药防治原发性骨质疏松症研究进展[J].辽宁中医药大学学报,2015,17(2):96-98．[4]王想福,孙凤歧,叶丙霖,等.破骨细胞与骨质疏松症的关系研究进展[J].中国骨质疏松杂志,2015,21(11):1420-1424.[5]覃裕,邱冰,朱思刚,等.仙灵骨葆胶囊治疗骨质疏松症的疗效及其对骨代谢及骨转换指标的影响分析[J].中国骨质疏松杂志,2015,21(9):1056-1060.[6]赵利敬,李沛.补肾中药干越骨质疏松症研究概况[J].中医学报,2015,30(9):1326-1328.[7]夏天爽,薛黎明,张巧,等.补肾阳与补肾阴中药抗骨质疏松作用的研究进展[J].药学实践杂志,2019,37(2):109-113.[8]朱开昕,苏本伟,赵明惠,等.中药桑寄生强筋骨的研究进展[J].中国处方药,2018,16(7):25-26.[9]李浩,戴燚,范彦博,等.杜仲补骨脂药对干预去势鼠成骨细胞增殖以及MMP3-OPN通路蛋白表达的研究[J].时珍国医国药,2016,27(7):1610-1613.[10]Wang Y,Zhou GJ,Yan ZX,et al.The protective effect of cyathuIaofficinalis kuan on bone in ovariectomized rats[J].Chin J Osteoporos,2015,21(8):918-921．[11]张乃丹.基于分子对接策略的熟地黄防治糖尿病性骨质疏松症有效成分及其作用机制研究[D].第二军医大学,2016.[12]Du XZ,Deng SL,Yang H.Clinical observation on Bushen HuoxueTongluo Decoction intreatment of glucocorticoid-inducedosteoporosis[J].Chinese Joumal of Experimental Traditional Medical Formulae,2017,23(4):193-197.

相似文献/References:

[1]杨 娜,周进平,林晓容,等.去睾丸老年大鼠血管钙化程度与骨代谢水平研究[J].医学信息,2019,32(04):5.[doi:10.3969/j.issn.1006-1959.2019.04.002]
　YANG Na,ZHOU Jin-ping,LIN Xiao-rong,et al.Study on the Degree of Vascular Calcification and Bone Metabolism in Aged Test Rats[J].Medical Information,2019,32(22):5.[doi:10.3969/j.issn.1006-1959.2019.04.002]

更新日期/Last Update: 1900-01-01